Lilly’s Amylin Drug Debate Intensifies Ahead of Crucial Weight-Loss Data

The debate centers on whether selective amylin activation is superior to dual amylin–calcitonin receptor agonism for obesity drugs. Eli Lilly’s eloralintide is designed to preferentially activate amylin receptors while minimizing calcitonin-receptor activity, which Lilly argues could improve tolerability.

Lilly’s Phase 2 study of 263 adults with overweight or obesity reported dose-dependent average weight loss after 48 weeks:
about 9% at 1 mg, 12% at 3 mg, 18% at 6 mg, and roughly 20% at 9 mg, versus 0.4% with placebo.

The results were strong enough for Lilly to advance eloralintide into Phase 3 development and explore combining it with tirzepatide, its GLP-1/GIP drug marketed as Zepbound and Mounjaro.

The key question for investors and clinicians is whether the apparent efficacy advantage will hold in larger, longer trials and whether side effects—particularly nausea and fatigue—can be controlled through dose escalation.

The competitive backdrop includes Novo Nordisk’s cagrilintide-based programs and CagriSema, which use broader amylin-pathway activity. The emerging design dispute could determine whether future obesity medicines favor selective amylin agonists or dual-receptor approaches.